NKTR logo

Nektar Therapeutics (NKTR)

$35.91

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on NKTR

Market cap

$1.23B

EPS

-5.99

P/E ratio

--

Price to sales

25.75

Dividend yield

--

Beta

1.454082

Price on NKTR

Previous close

$36.44

Today's open

$36.31

Day's range

$35.41 - $36.50

52 week range

$33.40 - $109

Profile about NKTR

CEO

Howard W. Robin

Employees

63

Headquarters

San Francisco, CA

Exchange

NASDAQ Capital Market

Shares outstanding

34214683

Issue type

Common Stock

NKTR industries and sectors

Healthcare

Biotechnology & Life Sciences

News on NKTR

Nektar Therapeutics (NKTR) Presents at UBS Global Biopharma Conference 2026 Transcript

Nektar Therapeutics ( NKTR ) UBS Global Biopharma Conference 2026 November 17, 2026 6:20 AM EST Company Participants Jonathan Zalevsky - Senior VP and Chief Research & Development Officer Conference Call Participants Alice Nettleton Presentation Alice Nettleton Good morning, everyone. Welcome to the next session at the UBS Global Biopharma Conference.

news source

Seeking Alpha • Nov 17, 2026

news preview

Nektar Therapeutics (NKTR) Q3 2026 Earnings Call Transcript

Nektar Therapeutics (NKTR) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 13, 2026

news preview

NKTR Q3 Earnings Beat Estimates, 2026 Revenue View Cut, Stock Down

Nektar beats Q3 earnings estimates with a narrower-than-expected loss, but lower 2026 revenue guidance sends shares down 4.5%.

news source

Zacks Investment Research • Nov 13, 2026

news preview

What Nektar Therapeutics (NKTR) Said on Its Q3 Earnings Call

Nektar Therapeutics NASDAQ: NKTR said it has initiated three Phase III studies of its experimental drug rezpegaldesleukin, or REZPEG, in atopic dermatitis and expects to begin a pivotal alopecia areata study in December, earlier than previously planned.

news source

MarketBeat • Nov 13, 2026

news preview

Nektar Therapeutics Announces Third Quarter 2026 Financial Results

SAN FRANCISCO, Nov. 12, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced its financial results for the third quarter ended September 30, 2026, and provided a business update. Cash and investments in marketable securities on September 30, 2026, were $952.9 million as compared to $245.8 million on December 31, 2025.

news source

PRNewsWire • Nov 12, 2026

news preview

Nektar Therapeutics (NKTR) Reports Q3 Loss, Lags Revenue Estimates

Nektar Therapeutics (NKTR) came out with a quarterly loss of $1.63 per share versus the Zacks Consensus Estimate of a loss of $2.16. This compares to a loss of $1.85 per share a year ago.

news source

Zacks Investment Research • Nov 13, 2026

news preview

Nektar Therapeutics to Participate in Two Investor Conferences in November

SAN FRANCISCO, Nov. 11, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that company management will be participating in two upcoming investor conferences. UBS Global Biopharma Conference Format: Fireside Chat and 1x1 meetings Fireside Chat Date: Tuesday, November 17, 2026 Fireside Chat Time: 11:20 – 11:50 a.m.

news source

PRNewsWire • Nov 11, 2026

news preview

Nektar Therapeutics: Focus Returns To The Strengths Of The Company

NKTR's rezpegaldesleukin is now in phase 3 trials in atopic dermatitis, but there is additional data from the company's phase 2b REZOLVE-AD trial expected in Q1'27. The market focus has shifting back to atopic dermatitis could be considered bullish, since the drug has impressed more in that indication previously. By comparison, an early October update from the alopecia areata trial, REZOLVE-AA, was met with selling.

news source

Seeking Alpha • Oct 30, 2026

news preview

Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Should You Buy?

Nektar (NKTR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

news source

Zacks Investment Research • Oct 29, 2026

news preview

Nektar Therapeutics to Announce Financial Results for the Third Quarter on Thursday, November 12, 2026, After Close of U.S.-Based Financial Markets

SAN FRANCISCO, Oct. 27, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter ended September 30, 2026 on Thursday, November 12, 2026, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m.

news source

PRNewsWire • Oct 27, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Nektar Therapeutics

Open an M1 investment account to buy and sell Nektar Therapeutics commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in NKTR on M1